Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas



Status:Terminated
Conditions:Liver Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:September 2007
End Date:August 2010

Use our guide to learn which trials are right for you!

Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101

An unmet medical need exists for the successful therapy of patients with advanced
hepatocellular and biliary tract malignances, with few and short lived disease responses to
chemotherapy for both advanced stage hepatic and biliary carcinomas. Pre-clinical data shows
cooperative antitumor activity between an epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor and taxanes. The efficacy of erlotinib in combination with docetaxel will
be assessed in this trial.

Outline: This is a multi-center study.

Patients who meet eligibility criteria will receive treatment as follows until disease
progression or excessive toxicities:

- Erlotinib 150 mg p.o. daily on days 2-7, 9-14, 16-28

- Docetaxel 30 mg/m2 IV over 30 min weekly x 3 weeks on days 1, 8, 15

Treatment cycle = 28 days

Performance Status: Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2

Life expectancy: At least 12 weeks

Hematopoietic:

- Absolute neutrophil count (ANC) > 1000 mm3

- Platelet count > 75,000 mm3

- Hemoglobin > 8 g/dL

Hepatic:

- Bilirubin < 2.0 x upper limit of normal (ULN)

- Transaminases (AST, ALT) < 5.0 x ULN if alkaline phosphatase is < 2.5 x ULN, or
alkaline phosphatase < 5 x ULN if transaminases are < 1.5 x ULN.

- If not on anticoagulation: PT < 4 seconds above ULN; INR < 1.5; PTT < 1.3 x ULN.

- If on therapeutic anticoagulation, patients may have an INR > 1.5 and PTT within
therapeutic range; INR will be monitored weekly until stable.

- Serum Albumin > 3.0

Renal:

- Creatinine clearance of > 60 ml/ min (by Cockcroft-Gault)

Pulmonary:

- Not specified

Inclusion Criteria:

- Histological or cytological proof of hepatocellular or biliary tract carcinomas, not
amenable to curative resection or transplantation.

- Prior cancer treatment completed at least 30 days prior to being registered for
protocol therapy and recovered from the acute toxicity effects of the regimen.

- Patients may have had radiofrequency ablation, cryosurgery or embolization, but must
have documented progressive disease with the involved lesion, or at least one
previously untreated lesion.

- Patients may have had ≤ 2 prior chemotherapy regimens.

- Prior radiation therapy allowed to < 25% of the bone marrow at least 30 days prior to
being registered for protocol therapy.

- Patients with biliary obstruction must have percutaneous transhepatic drainage or
endoscopic stent placement prior to starting study treatment.

- Patients with a history of malignancy are eligible provided they have been curatively
treated and demonstrate no evidence for recurrence of that cancer.

- Peripheral neuropathy ≤ grade 1.

- Patients must agree to abstain from frozen or fresh grapefruit or grapefruit juice
for 5 days prior to, and during treatment.

- Patients must be willing to use an effective method of contraception (hormonal or
barrier method of birth control; abstinence) while on treatment and for a 12 week
period thereafter.

- Females of childbearing potential must have a negative pregnancy test within 7 days
prior to being registered for protocol therapy.

- Written informed consent and HIPAA authorization for release of personal health
information.

- Age ≥ 18 years at time of consent.

Exclusion Criteria:

- No previous treatment with EGFR inhibitors.

- No treatment with any investigational agent within 30 days prior to being registered
for protocol therapy.

- No symptomatic brain metastasis. A subject with prior brain metastasis may be
considered if they have completed their treatment for brain metastasis, no longer
require corticosteroids, and are asymptomatic.

- No Child-Pugh B or C liver cirrhosis.

- No active corneal erosions or history of abnormal corneal sensitivity test.

- No history of aneurysm or arteriovenous malformation.

- No hemorrhage/bleeding event > CTCAE Grade 3 within 30 days prior to begin registered
for protocol therapy.

- No clinically significant infections as judged by the treating investigator.

- No condition that impairs patient's ability to swallow whole pills.

- No history of hypersensitivity to docetaxel or other drugs formulated with
polysorbate 80.

- Females must not be breastfeeding.

- Patients who cannot avoid the following medications will be ineligible for the trial:
midazolam, anti-mycotic agents (ketoconazole and related compounds), macrolide
antibiotics (erythromycin and related compounds), nifedipine, phenobarbital,
phenytoin, carbamazepine, and rifampin (induction) and anti-retrovirals (including
ritonavir, saquinavir).
We found this trial at
12
sites
660 S Euclid Ave
St. Louis, Missouri 63110
(800) 600-3606
Siteman Cancer Center The Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University...
?
mi
from
St. Louis, MO
Click here to add this to my saved trials
Bloomington, Indiana 47403
?
mi
from
Bloomington, IN
Click here to add this to my saved trials
303 E Chicago Ave
Chicago, Illinois 60611
(312) 503-8194
Northwestern University Feinberg School of Medicine Northwestern University Feinberg School of Medicine, founded in 1859,...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Fort Wayne, Indiana 46815
?
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Indianapolis, Indiana 46202
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Indianapolis, Indiana 46202
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Indianapolis, Indiana 46202
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Muncie, Indiana 47303
?
mi
from
Muncie, IN
Click here to add this to my saved trials
Newark, Delaware 19713
?
mi
from
Newark, DE
Click here to add this to my saved trials
Omaha, Nebraska 68114
?
mi
from
Omaha, NE
Click here to add this to my saved trials
615 N Michigan Street
South Bend, Indiana 46601
(574) 647-7370
Northern Indiana Cancer Research Consortium The Northern Indiana Cancer Research Consortium (NICRC) is comprised of...
?
mi
from
South Bend, IN
Click here to add this to my saved trials